CNTX - MCRB MRTX and CNTX among pre market gainers
Seres Therapeutics (MCRB) +11% announces confirmatory results from investigational microbiome therapeutic SER-109 ECOSPOR IV open-label study in recurrent C. difficile infection. Kohl's KSS +10% after entering exclusive talks for $60/share sale to Franchise Group. GitLab GTLB +9% on Q1 earning beat. Dave & Buster's PLAY +5% on Q1 results. Context Therapeutics (CNTX) +5%. BuzzFeed BZFD +5% amid lockup expiration. Mirati Therapeutics (MRTX) +5%.
For further details see:
MCRB, MRTX and CNTX among pre market gainers